-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
PTGX Stock: The FDA News That Has Protagonist Therapeutics Investors Cheering Today
PTGX Stock: The FDA News That Has Protagonist Therapeutics Investors Cheering Today
InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Protagonist Therapeutics (NASDAQ:PTGX) stock is rocketing higher on Monday thanks to an update from the U.S. Food and Drug Administration (FDA) concerning rusfertide clinical studies.
Source: JHVEPhoto / Shutterstock.com
According to a news release, Protagonist Therapeutics has to go ahead to resume dosing in its rusfertide clinical trials. This was previously on hold following concerns from the FDA brought up on Sept. 17.
The FDA required extra information and steps about the trials before they could resume. Protagonist Therapeutics met those requirements by submitting individual patient clinical safety reports, updating the investigator brochure and patient informed consent forms, performing a comprehensive review of the most recent safety database, as well as including new safety and stopping rules in the study protocols.
The 7 Best Consumer Discretionary Stocks To Buy for Q4 2021
Dinesh Patel, Ph.D., president and CEO of Protagonist Therapeutics, said the following about today's news.
"Patient safety continues to be our topmost priority. We believe that the cumulative evidence regarding the safety and clinical risk-benefit of rusfertide is supportive of expedited clinical development."
Protagonist Therapeutics notes that it's moving forward with study plans, which include its Phase 3 registrational study for polycythemia vera. It expects to start that in the first quarter of 2022.
PTGX stock is performing well today following the FDA update. As a result, some 17 million shares of the stock are trading hands. That's a hefty increase over its daily average trading volume of about 1 million shares.
PTGX stock was up 87.5% as of Monday morning. That has it well on its way to recovering the losses it experienced dosing was halted in September.
Investors looking for more recent stock market news will want to stick around!
We've got plenty of stock coverage that traders need to know about. That includes this morning's biggest pre-market stock movers, an update on a Bitcoin (CCC:BTC-USD) ETF, as well as reactions to Camber Energy (NYSE:CEI) strong rise last week. You can find all of that information by checking out the links below!
More Recent Stock Market News
Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Bitcoin ETF Approved? Um, Sorta. 7 Things to Know About the Volt Equity ETF (BTCR).
What CEI Stock Investors Are Saying After Camber Energy's Red-Hot Week
On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
The post PTGX Stock: The FDA News That Has Protagonist Therapeutics Investors Cheering Today appeared first on InvestorPlace.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips
InvestorPlace-股市新闻、股票咨询和交易提示
Protagonist Therapeutics (NASDAQ:PTGX) stock is rocketing higher on Monday thanks to an update from the U.S. Food and Drug Administration (FDA) concerning rusfertide clinical studies.
主角治疗学纳斯达克市场代码：PTGX)的股票周一大幅上涨，这要归功于美国食品和药物管理局(FDA)关于芦荟肽临床研究的最新消息。
Source: JHVEPhoto / Shutterstock.com
来源：JHVEPhoto/Shutterstock.com
According to a news release, Protagonist Therapeutics has to go ahead to resume dosing in its rusfertide clinical trials. This was previously on hold following concerns from the FDA brought up on Sept. 17.
根据一份新闻稿，主角治疗公司必须继续在其黄曲霉毒素临床试验中恢复剂量。此前，在FDA于9月1日提出担忧后，这一点被搁置。17.
The FDA required extra information and steps about the trials before they could resume. Protagonist Therapeutics met those requirements by submitting individual patient clinical safety reports, updating the investigator brochure and patient informed consent forms, performing a comprehensive review of the most recent safety database, as well as including new safety and stopping rules in the study protocols.
FDA要求提供有关试验的额外信息和步骤，然后才能恢复试验。Protagant Treeutics公司通过提交个别患者的临床安全报告，更新研究人员手册和患者知情同意书，对最新的安全数据库进行全面审查，以及在研究方案中纳入新的安全和停止规则，满足了这些要求。
The 7 Best Consumer Discretionary Stocks To Buy for Q4 2021
2021年第四季度最值得购买的7只非必需消费品股票
Dinesh Patel, Ph.D., president and CEO of Protagonist Therapeutics, said the following about today's news.
主人公治疗公司总裁兼首席执行官迪内什·帕特尔博士就今天的新闻说了下面的话。
"Patient safety continues to be our topmost priority. We believe that the cumulative evidence regarding the safety and clinical risk-benefit of rusfertide is supportive of expedited clinical development."
患者安全仍然是我们最优先考虑的问题。我们相信，有关芦荟肽安全性和临床风险效益的累积证据支持加快临床开发。“
Protagonist Therapeutics notes that it's moving forward with study plans, which include its Phase 3 registrational study for polycythemia vera. It expects to start that in the first quarter of 2022.
Protagant Treateutics指出，该公司正在推进研究计划，其中包括真性红细胞增多症的第三阶段注册研究。该公司预计将在2022年第一季度启动这一计划。
PTGX stock is performing well today following the FDA update. As a result, some 17 million shares of the stock are trading hands. That's a hefty increase over its daily average trading volume of about 1 million shares.
随着FDA的更新，PTGX的股票今天表现良好。因此，该股约有1700万股易手。这比其约100万股的日均成交量大幅增加。
PTGX stock was up 87.5% as of Monday morning. That has it well on its way to recovering the losses it experienced dosing was halted in September.
截至周一上午，PTGX股价上涨87.5%。这让它很好地恢复了在9月份被停止服药的损失。
Investors looking for more recent stock market news will want to stick around!
寻找更多最新股市消息的投资者将会想要留下来！
We've got plenty of stock coverage that traders need to know about. That includes this morning's biggest pre-market stock movers, an update on a Bitcoin (CCC:BTC-USD) ETF, as well as reactions to Camber Energy (NYSE:CEI) strong rise last week. You can find all of that information by checking out the links below!
我们有大量的股票报道，交易员需要了解。这包括今天上午最大的盘前股票涨幅，最新的比特币(CCC：BTC-USD)ETF，以及对弧形能源(纽约证券交易所代码：CEI)上周强劲上涨。您可以通过查看下面的链接找到所有这些信息！
More Recent Stock Market News
最近的股市新闻
Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Bitcoin ETF Approved? Um, Sorta. 7 Things to Know About the Volt Equity ETF (BTCR).
What CEI Stock Investors Are Saying After Camber Energy's Red-Hot Week
今日最大的盘前炒股：周一涨幅最大的10只股票和输家最多的10只股票
比特币ETF获批？嗯，索尔塔。关于Volt Equity ETF(BTCR)需要知道的7件事。
中东欧股票投资者在Camber Energy火热的一周后说些什么
On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
在出版之日，威廉·怀特没有(直接或间接)持有本文所述证券的任何头寸。本文表达的观点是作者的观点，以InvestorPlace.com为准出版指南.
The post PTGX Stock: The FDA News That Has Protagonist Therapeutics Investors Cheering Today appeared first on InvestorPlace.
PTGX股票的帖子：FDA新闻，主角治疗投资者今天欢呼，它首先出现在InvestorPlace上。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧